Skip to main content

Table 1 Patient baseline characteristics and transplant details

From: Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience

Total number of adult patients 70
Median (range) age (years) 35.9 (19–59)
Gender (%) 57 (81.4%) female
Disease subtype 67 (95.7%) diffuse
Median (range) disease duration (years)a 2 (1–7)
Organ involvement:
 Skin n (%) 70/70 (100%)
 Interstitial lung disease, n (%) 59/70 (84.2%)
 Pulmonary hypertension, n (%) 4/70 (5.7%) mild
 Heart involvement, n (%) 32/70 (45.7%)b
 Gastrointestinal, n (%) 57/62 (92%)
 Kidney n 0
 Positive anti-SCl70 antibodies, n (%) 43/64 (67.2%)
Previous immunosuppressive treatment:
 Methotrexate, n (%) 26/70 (37.1%)
 Cyclophosphamide, n (%) 48/70 (68.6%)
 Mycophenolate mofetil, n (%) 13/70 (18.6%)
 Rituximab, n (%) 4/70 (5.7%)
Transplant regimen:
 Cyclophosphamide + ATG 65 (92.8%)
 Fludarabine + Melphalan + ATG 5 (7.2%)
  1. Baseline (pre-transplant) clinical characteristics of patients enrolled in the study
  2. IV intravenous infusion, ATG anti-thymocyte globulin
  3. aDisease duration from first non-Raynaud’s phenomenon clinical manifestation until transplant
  4. bPatients with severe heart involvement were excluded from transplant